Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne, commemorated its 30th ...

Columnist Shalom Lim tells an international conference about his experiences with inclusion during his education in Singapore ...

Capricor Therapeutics (CAPT) stock in focus as company receives Orphan Drug and ATMP designations from the EU regulator for its lead drug deramiocel. Read more here.

Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...

Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...